Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed ...
Cassava Sciences will discontinue its potential Alzheimer's treatment after recent trials showed no improvement to cognitive or functional decline. Shares halted from trading ahead of the morning bell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback